A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer

被引：0
|
作者：
He, Wen-zhuo
Jiang, Chang
Yi, Jiahong
Xue, Ju
Yin, Zhao-feng
Dong, Wen-jing
Xia, Liang-Ping
机构：
[1] Sun Yat Sen Univ, Dept VIP Reg, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Peoples R China
[4] Zhongshan City Peoples Hosp, Zhongshan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3534
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ozaka, Masato
    Ogura, Mariko
    Chin, Keisho
    Yamaguchi, Toshiharu
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1653 - 1662
  • [42] SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Cohn, Allen
    Dakhil, Shaker
    Saleh, Mansoor
    Piperdi, Bilal
    Cline-Burkhardt, Mika
    Tian, Ying
    Go, William Y.
    CLINICAL COLORECTAL CANCER, 2015, 14 (02) : 72 - 80
  • [43] Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer
    Huang, Weizhen
    Zhang, Hang
    Tian, Yunming
    Cha, Yinlian
    Xiong, Hailin
    Yuan, Xia
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (04) : 531 - 538
  • [44] FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
    Giordano Domenico Beretta
    Fausto Petrelli
    Sergio Stinco
    Mary Cabiddu
    Mara Ghilardi
    Michela Squadroni
    Karen Borgonovo
    Sandro Barni
    Medical Oncology, 2013, 30
  • [45] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
    Ranhua Cao
    Shuai Zhang
    Dedong Ma
    Likuan Hu
    Medical Oncology, 2015, 32
  • [46] A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
    Liu, Yuguo
    Luan, Lijuan
    Wang, Xingli
    ONCOTARGETS AND THERAPY, 2015, 8 : 1061 - 1068
  • [47] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
    Cao, Ranhua
    Zhang, Shuai
    Ma, Dedong
    Hu, Likuan
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
  • [48] Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
    Fang, Xuefeng
    Zhu, Ning
    Zhong, Chenhan
    Wang, Liuhong
    Li, Jun
    Weng, Shanshan
    Hu, Hanguang
    Dong, Caixia
    Li, Dan
    Song, Yongmao
    Xu, Dong
    Wang, Jianwei
    Sun, Lifeng
    Wang, Jian
    Wang, Zhanhuai
    Cao, Hongfeng
    Liao, Xiujun
    Yu, Ningjuan
    Xiao, Qian
    Mi, Mi
    Zhang, Suzhan
    Ding, Kefeng
    Yuan, Ying
    ECLINICALMEDICINE, 2023, 62
  • [49] Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
    Sunakawa, Y.
    Satake, H.
    Usher, J.
    Jaimes, Y.
    Miyamoto, Y.
    Nakamura, M.
    Kataoka, M.
    Shiozawa, M.
    Takagane, A.
    Terazawa, T.
    Watanabe, T.
    Ishiguro, K.
    Tanaka, C.
    Takeuchi, M.
    Fujii, M.
    Danenberg, K.
    Danenberg, P., V
    Lenz, H-J
    Sekikawa, T.
    Ichikawa, W.
    ESMO OPEN, 2022, 7 (03)
  • [50] Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
    Wang, Yanrong
    Jia, Ru
    Si, Haiyan
    Ma, Yue
    Fan, Mengjiao
    Zhang, Nan
    Liu, Fangfang
    Shi, Yue
    Jia, Yushan
    Zhang, Yaoyue
    Han, Quanli
    Wang, Zhikuan
    Dai, Guanghai
    BMC CANCER, 2025, 25 (01)
12345